Table: Towa Pharmaceutical - 9-MTH group results
Feb 13 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2024 Dec 31, 2023 Mar 31, 2025
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 193.74 168.33 262.10
(+15.1 pct) (+19.9 pct) (+15.0 pct)
Operating 18.61 13.20 23.30
(+40.9 pct) (+146.7 pct) (+32.0 pct)
Recurring 21.76 17.17 22.70
(+26.7 pct) (+270.0 pct) (-7.3 pct)
Net 14.62 11.52 15.00
(+27.0 pct) (+480.4 pct) (-7.3 pct)
EPS 297.10 yen 234.03 yen 304.72 yen
Ann Div 60.00 yen 70.00 yen
-Q2 div 30.00 yen 30.00 yen
-Q4 div 30.00 yen 40.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results